Repros Therapeutics Analyst Brief Report; Androxal(R) Achieves Superiority in Top Line Analysis by Small Cap Street …

NEW YORK, Sept. 29, 2014 /PRNewswire-USNewswire/ --Androxal(R) Second Pivotal Study from Repros Therapeutics Inc. (NASDAQ: RPRX) a development stage biopharmaceutical company, achieves superiority in top line analysis for both co-primary endpoints compared to marketed topical gel in the treatment of secondary hypogonadism.

However, the conclusions of the FDA Advisory Panel that met on Wednesday, September 17, 2014, to discuss the appropriate population suited to testosterone replacement therapy (TRT), were not directly related to Androxal(R), since Androxal(R) is not a form of testosterone. The FDA panelists voted to recommend that testosterone replacement class label should be changed, narrowing the treatment option to those with indications such as testes, pituitary or hypothalamus impairment, and excluding age-related hypogonadism, which the panel considered as a normal sign of aging.

An analyst report on Repros can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:

http://bit.ly/-RPRX-AnalystBrief

Copy and paste to browser may be required.

About Small Cap Street

Once you read our reports written by our team of financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties at no cost.

Our Financial Analysts spend countless hours researching stocks. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges. These reports include a straightforward assessment of the company by a financial analyst who has pledged to remain free of influence when writing research reports.

Forward-Looking Disclaimer

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

The rest is here:
Repros Therapeutics Analyst Brief Report; Androxal(R) Achieves Superiority in Top Line Analysis by Small Cap Street ...

Word Count: 363